The RACGP eTG Update Library: High-Yield Clinical Guideline Shifts for the AKT and KFP

Australian general practice clinical guidelines are a moving target. To ensure that the AKT and KFP exams evaluate candidates on safe, current, and evidence-based practice, the RACGP examiner panels systematically update exam questions to reflect the latest changes in clinical standards.

Relying on old study notes, outdated textbooks, or stagnant question databases is one of the leading causes of candidate error on exam day. In a high-stakes environment where a single mark can determine whether you pass the hurdle, studying obsolete guidelines (such as the old Framingham cardiovascular tables or outdated asthma stepwise schedules) represents a significant, preventable risk.

This reference guide provides an exhaustive, data-backed summary of the most critical clinical guideline shifts across cardiology, endocrinology, respiratory medicine, and preventive screening. It translates complex guideline documents into high-yield exam takeaways, ensuring you are equipped with up-to-date, safe clinical knowledge before sitting the AKT and KFP.

The Therapeutic Guidelines (eTG), the RACGP Red Book, and the Australian Immunisation Handbook constitute the primary sources of truth for both exams. Let's map the most significant updates in these core documents that are guaranteed to appear in your clinical stems.

Cardiology: The 2023 CVD Risk Calculator

The release of the 2023 Australian Guideline for Assessing and Managing Cardiovascular Disease Risk represents the most significant cardiology shift in a decade. The old Framingham risk equation has been completely retired, replaced by the new **Australian Cardiovascular Disease Risk Calculator (AusCVDRisk)**.

The new calculator is optimized specifically for the Australian population, incorporating advanced risk factors and modifying guidelines to target preventive interventions earlier in life.

You must also memorize the high-risk conditions where a patient is considered to have **automatic high CVD risk** (10% or greater) and does not require a calculator assessment:

• Established atherosclerotic cardiovascular disease (myocardial infarction, stroke, or peripheral arterial disease)
• Diabetes mellitus and aged over 60 years
• Diabetes mellitus with microalbuminuria (ACR greater than 2.5 mg/mmol for males, 3.5 mg/mmol for females)
• Moderate to severe Chronic Kidney Disease (eGFR less than 45 mL/min/1.73m²)
• Familial Hypercholesterolaemia (confirmed or suspected with cholesterol greater than 7.5 mmol/L)
• Severe hypertension (systolic BP 180 mmHg or greater, or diastolic BP 110 mmHg or greater)

Endocrinology: Diabetes Cardiorenal Protection

In endocrinology, the stepwise management of Type 2 Diabetes Mellitus (T2DM) has moved beyond simple glycemic control. Current eTG and RACGP guidelines prioritize the use of specific glucose-lowering agents for their systemic organ-protective benefits, regardless of the patient's baseline HbA1c.

When managing a diabetic patient, your primary decision is no longer just how to lower blood glucose, but whether the patient possesses cardiorenal risk factors that demand target-specific pharmacotherapy.

• Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: Drugs like dapagliflozin and empagliflozin must be prioritized in patients with established heart failure (reduced or preserved ejection fraction) or Chronic Kidney Disease (with eGFR between 25 and 60 mL/min/1.73m² or ACR greater than 3 mg/mmol). These agents provide profound cardiovascular and renal protection.
• Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Agents like semaglutide must be prioritized in patients with established atherosclerotic cardiovascular disease where glycemic targets are not met with Metformin alone, especially where weight management represents a primary clinical goal.
• Safe eGFR Thresholds: You must know the safety limits for these medications. Metformin must be dose-reduced if eGFR drops below 45 mL/min/1.73m², and ceased entirely if eGFR drops below 30 mL/min/1.73m². SGLT2 inhibitors should generally not be initiated for glycemic control if eGFR is below 45 mL/min/1.73m², but they can be safely continued down to an eGFR of 25 mL/min/1.73m² specifically for renal protection.

Respiratory: Asthma Relievers & COPD Triple Therapy

Respiratory medicine guidelines have seen massive adjustments designed to reduce patient mortality and improve systemic management consistency.

1. Asthma Management (Version 2.2 Guidelines)

The National Asthma Council (Australian Asthma Handbook) has solidified a fundamental paradigm shift: **SABA-only management is no longer recommended**. Relying solely on short-acting beta-agonists (like salbutamol) as a reliever is considered unsafe because it does not address the underlying airway inflammation, leaving the patient at high risk of severe flare-ups.

The new gold standard reliever strategy utilizes a **combination low-dose inhaled corticosteroid and fast-acting beta-agonist (ICS-formoterol)**, such as budesonide-formoterol. Under the current stepwise model:

• Step 1 and 2 (Mild Asthma): Patients should use low-dose ICS-formoterol on an as-needed basis as their primary reliever. This provides immediate symptom relief while delivering a protective dose of anti-inflammatory corticosteroid at the exact moment of airway irritation.
• Step 3 and 4 (Moderate Asthma): Patients transition to a maintenance-and-reliever therapy (MART) regimen, using low-dose ICS-formoterol as both their daily controller and their as-needed reliever.

2. COPD Titration

COPD guidelines have simplified the titration pathway. In symptomatic patients with frequent exacerbations, we transition from single bronchodilator therapy to dual bronchodilation (LAMA plus LABA).

**Triple Therapy** (LAMA plus LABA plus ICS) is strictly indicated only for patients who experience recurrent exacerbations despite optimal dual bronchodilation, particularly where blood eosinophil counts are elevated (greater than 300 cells/microliter) or where there is a confirmed overlap with asthma.

Preventive Screening: NCSP Cervical Exit Pathways

The National Cervical Screening Program (NCSP) is highly protocol-driven, and you must know the exact diagnostic pathways. The most high-yield recent update focuses on the **cervical screening exit pathway**.

A common exam scenario involves determining when a woman can safely exit the cervical screening register. Under the current protocol, women are eligible to exit the program between **70 and 74 years of age**.

To exit safely, the patient must meet the following criteria:

1. 1
   Aged between 70 and 74 years

   The patient must fall within this specific age bracket to be eligible for the exit protocol.

2. 2
   A last routine screen performed at or after age 65

   The patient must have a documented screening test taken after their 65th birthday.

3. 3
   An oncogenic HPV "not detected" result

   The final exit test must be negative for oncogenic HPV strains. If HPV is detected, the patient must remain on the surveillance pathway until they meet the criteria for a safe return to routine screening or exit.

Immunisation Highlights

The Australian Immunisation Handbook updates require candidates to know exact vaccine schedules, especially for vulnerable populations:

• Pneumococcal Vaccines: Know the distinct pathways for healthy adults aged 70 years and over (who receive a single dose of 20-valent pneumococcal conjugate vaccine, Prevenar 20) vs. Aboriginal and Torres Strait Islander adults (who receive Prevenar 20 at age 50).
• Shingles Prevention: Shingrix (recombinant subunit vaccine) has replaced Zostavax (live attenuated vaccine) on the NIP. Shingrix is free for adults aged 65 years and over, Aboriginal and Torres Strait Islander peoples aged 50 years and over, and immunocompromised individuals aged 18 years and over with specific medical conditions. Know that it is a 2-dose course.

Maintaining Alignment with FellowPath

When preparing for the AKT and KFP, studying questions that use outdated clinical guidelines is actively dangerous. It trains your brain to recognize incorrect diagnostic and management patterns, leading to critical errors on exam day.

At FellowPath, we ensure that you are never caught out by moving guidelines. Our clinical team reviews every single question in our bank continuously, mapping every case strictly to the current editions of the Therapeutic Guidelines (eTG) and the RACGP Red Book.

Frequently Asked Questions